Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 17/20 | 0.84 |
| ▸ | ITK | Q08881 | 2/20 | 0.70 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | BTK | Q06187 | 2/20 | 0.66 |
| ▸ | CDK2 | P24941 | 2/20 | 0.65 |
| ▸ | TXK | P42681 | 1/20 | 0.64 |
| ▸ | MET | P08581 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655992 | 0.91 | NTRK1 (1.00) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL14460950 | 0.91 | NTRK1 (0.88) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL14460947 | 0.90 | NTRK1 (0.87) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL5657610 | 0.90 | NTRK1 (0.84) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL14460971 | 0.89 | NTRK1 (0.82) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL5659174 | 0.88 | NTRK1 (0.81) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL14460926 | 0.87 | NTRK1 (0.79) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL14460610 | 0.86 | NTRK1 (0.77) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL14460962 | 0.86 | NTRK1 (0.79) | NTRK1ITKJAK3BTKCDK2 | |
| SCHEMBL5658319 | 0.85 | NTRK1 (0.77) | NTRK1ITKJAK3BTKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241781-B2 | 2-(pyridinylamino)thiazolylthio(optional methyl)-benzamides or -benzenealkanamides; may also contain antiinflammatory agents, antiproliferative agents, anticancer agents or anticytotoxic agents. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241781-B2 | 2-(pyridinylamino)thiazolylthio(optional methyl)-benzamides or -benzenealkanamides; may also contain antiinflammatory agents, antiproliferative agents, anticancer agents or anticytotoxic agents. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241781-B2 | 2-(pyridinylamino)thiazolylthio(optional methyl)-benzamides or -benzenealkanamides; may also contain antiinflammatory agents, antiproliferative agents, anticancer agents or anticytotoxic agents. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7037926-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060030598-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C | 2006-02-09 | — | — | US | disclosed |
| US-6953795-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-6706717-B2 | ANTICANCER AGENTS; IMMUNOLOGY DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030598-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | NTRK1 625/4885ITK 10/4885JAK3 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.